Human Papillomavirus

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

2100%

+ 26 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Sharp TherapeuticsPA - Pittsburgh

8 programs

V503Phase 3

GardasilPhase 2

Gardasil vaccineN/AVaccine

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A

+3 more programs

MSDIreland - Ballydine

8 programs

V503Phase 3

GardasilPhase 2

Gardasil vaccineN/AVaccine

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A

+3 more programs

GenexineKorea - Seoul

1 program

GX-I7Phase 11 trial

Active Trials

NCT03144934Completed32Est. Mar 2018

Merck & Co.RAHWAY, NJ

5 programs

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With MenN/A1 trial

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)N/A1 trial

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)N/A1 trial

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)N/A1 trial

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College N/A1 trial

Active Trials

NCT01422356Completed200Est. Sep 2013

NCT01159834Completed1,574Est. Dec 2011

NCT03000933Completed200Est. Dec 2019

+2 more trials

AbbottABBOTT PARK, IL

1 program

Alinity m HR HPVN/A1 trial

Active Trials

NCT04746872Completed14,935Est. Nov 2022

Alliance PharmaceuticalsUK - Wiltshire

1 program

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)N/A

Angeles TherapeuticsCA - Los Angeles

1 program

Natural History of HPV From Infection to Neoplasia in Adolescents and Young WomenN/A1 trial

Active Trials

NCT01366742Completed900Est. May 2016

Allergy TherapeuticsUK - West Sussex

1 program

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)N/A1 trial

Active Trials

NCT05026138Recruiting850Est. Mar 2047

PfizerNEW YORK, NY

1 program

ParticipatoryN/A1 trial

Active Trials

NCT02377843Completed30Est. Mar 2016

Human BioSciencesWV - Martinsburg

1 program

ParticipatoryN/A

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

GenexineGX-I7

Allergy TherapeuticsNatural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

AbbottAlinity m HR HPV

Merck & Co.Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

PfizerParticipatory

Merck & Co.Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Merck & Co.KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

Merck & Co.Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Merck & Co.Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Angeles TherapeuticsNatural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Clinical Trials (10)

Total enrollment: 20,217 patients across 10 trials

NCT03144934 GenexineGX-I7

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Start: Feb 2017Est. completion: Mar 201832 patients

Phase 1Completed

NCT05026138 Allergy TherapeuticsNatural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

Start: Nov 2021Est. completion: Mar 2047850 patients

N/ARecruiting

NCT04746872 AbbottAlinity m HR HPV

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

Start: Feb 2021Est. completion: Nov 202214,935 patients

N/ACompleted

NCT03000933 Merck & Co.Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)

Start: Jan 2017Est. completion: Dec 2019200 patients

N/ACompleted

NCT02377843 PfizerParticipatory

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

Start: Mar 2015Est. completion: Mar 201630 patients

N/ACompleted

NCT01289873 Merck & Co.Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women

Start: May 2011Est. completion: Sep 20121,036 patients

N/ACompleted

NCT01314404 Merck & Co.KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

Start: Mar 2011Est. completion: Sep 2012460 patients

N/AUnknown

NCT01422356 Merck & Co.Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men

Start: Sep 2010Est. completion: Sep 2013200 patients

N/ACompleted

NCT01159834 Merck & Co.Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Start: Sep 2010Est. completion: Dec 20111,574 patients

N/ACompleted

NCT01366742 Angeles TherapeuticsNatural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Start: Dec 1987Est. completion: May 2016900 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 20,217 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.